Can Modicare Reshape India’s Health Care Paradigm?
India’s new government-funded health care program expects to expand access to treatment to more than 100 million families. Can it effectively deliver on its promise and also materially expand opportunities for hospitals and pharma?
You may also be interested in...
Scrip delves into some key trends that could play out in 2020 to shape and impact Indian pharmaceutical firms. Keep an eye on opportunities in key markets like China and the US, and on private equity interest in “control deals” and trade margin-related tweaks on the Indian market.
With a broader ecosystem of prescription influencers emerging rapidly in India, pharma needs to engage with these groups extensively, a conference in Mumbai hears.
Increasing local content requirements have been stipulated in the public purchase preference norms for medicines in India. Backward-integrated Indian firms stand to gain but progressive localization requirements for drugs not made in India appear to be a tough ask.